The specificity of the ELISA kit was 97.5%, as examined against total 412 normal human samples. Using Chinese hamster ovarian (CHO) cell-expressed full-length SARS-CoV-2 S1 protein as capturing antigen, a coronavirus disease 2019 (COVID-19)/SARS-CoV-2 S1 serology enzyme-linked immunosorbent assay (ELISA) kit was developed and validated with negative samples collected prior to the outbreak or during the outbreak and positive samples from patients confirmed with COVID-19. Such loss could be prevented if there were a serologic assay for SARS-CoV-2-specific antibodies for serological surveillance of its infection at the early stage of disease.

Thousands of medical staff have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with hundreds of deaths reported.

12 Hubei Provincial Center for Disease Control and Prevention, Wuhan, China.

11 ShaanXi Provincial Engineering Research Center for Nano-BioMedical Detection, Xi'an, Shaanxi, China.

10 Department of Laboratory, Quzhou People's Hospital, Quzhou, Zhejiang, China.

9 Bengbu Medical University, Bengbu, Anhui, China.

8 School of Biotechnology, Jiangnan University, Wuxi, Jiangsu, China.

7 Treatment and Research Center for Infectious Diseases, Fifth Medical Center of People's Liberation Army General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.

6 Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.

5 Beijing YouAn Hospital, Capital Medical University, Beijing, China.

4 ZhenGe Biotechnology Co, Ltd, Shanghai, China.

3 Research Network of Immunity and Health, Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, China.

2 AbMax Biotechnology Co, Ltd, Beijing, China.1 AnyGo Technology Co, Ltd, Beijing, China.

Squere anygo